Status:

RECRUITING

Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation

Lead Sponsor:

Hopital Foch

Conditions:

Lung Transplant Rejection

Lung Transplant Failure

Eligibility:

All Genders

15+ years

Phase:

NA

Brief Summary

Transplant results vary considerably from one organ to another. Lung transplantation has poorer long-term outcomes than other solid organ transplants, with a current median post-transplant survival of...

Eligibility Criteria

Inclusion

  • Men or women over 15 years of age
  • Suffering from a lung condition requiring a transplant planned at Foch Hospital or being followed up at Foch Hospital following a lung transplant
  • Have signed the informed consent form and for patients aged 15 to 18 years that the person(s) exercising parental authority has/have signed the informed consent.
  • Be affiliated with a Health Insurance plan.

Exclusion

  • Pregnant, parturient and/or lactating woman
  • Hemoglobin level less than or equal to 8g/dl
  • Persons of full age who are subject to a legal protection measure or who are unable to express their consent
  • Persons under the protection of justice
  • Not being able to follow the study requirements for geographical, social or psychological reasons
  • Patient refusal.

Key Trial Info

Start Date :

March 17 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 1 2037

Estimated Enrollment :

900 Patients enrolled

Trial Details

Trial ID

NCT04837339

Start Date

March 17 2022

End Date

March 1 2037

Last Update

August 3 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Roux

Suresnes, France

Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation | DecenTrialz